We have selected atogepant for preventing migraine for a pilot for the proportional approach to technology appraisals sub process: a streamlined approach to Cost Comparison Appraisals.
We believe efficiencies can be made to the current cost comparison approach which would result in a faster route to a recommendation for companies, quicker access for patients and a less resource intensive process for all involved. There will be a shorter submission period and external assessment group (EAG) review of the company’s evidence submission. In late April 2023, NICE will advise a subset of the committee (the chair and vice chair) of the appropriateness of cost comparison. This subset will review the evidence online over a set period and be able to make a recommendation outside of a full committee meeting. This will not alter standard governance or appeal processes and maintains the independence of the committee as a decision-making body.